News
-
NZ holds off on codeine decision
Friday | Jul 7 2017THE Medicines Classification Committee of NZ's Medsafe has stopped short of rescheduling OTC medications containing codeine, with the minutes of its latest meeting detailing questions which would be required to be answered "to allow codeine to continue to be available without prescription".
-
Guild corporate vax plan win
Friday | Jul 7 2017THE Pharmacy Guild of Australia's Queensland Branch has announced the success of the 2017 Guild Corporate Vaccination Program, supporting member pharmacies to administer influenza vaccinations to employees from five State Government departments (PD 12 May).
-
ASMI supports OTC PPIs
Friday | Jul 7 2017THE Australian Self Medication Industry (ASMI) has stated that consumers can have confidence in the safety profile and effectiveness of over-the counter (OTC) Proton Pump Inhibitors (PPIs) when they are used as recommended.
-
The Beauty of You campaign
Friday | Jul 7 2017PRICELINE Pharmacy has announced the launch of its "The Beauty of You" campaign today, "celebrating the diversity and uniqueness of every Australian woman" through its store network and website.
-
Amcal pathology disarray
Friday | Jul 7 2017AMCAL'S controversial new in-pharmacy pathology screening service has been struck a blow with provider Sonic Healthcare advising it is withdrawing its support for the program (PD breaking news).
-
PD breaking news – Sigma pharmacy pathology screening provider pulls out
Thursday | Jul 6 2017Sonic Healthcare withdraws services which underpinned the new Amcal service.
-
-
Dispensary Corner 06 July 17
Thursday | Jul 6 2017NEW Zealand's Maori language has just been expanded by 200 additional words and phrases, and most of the additions are related to health issues.
-
Indication extensions
Thursday | Jul 6 2017THE Australian Register of Therapeutic Goods (ARTG) has listed new or extended uses for four products effective from Jun: Opdivo (nivolumab) sponsored by Bristol-Myers Squibb for Hodgkin lymphoma; Ozurdex (dexamethasone) by Allergan for macular oedema; Pfizer's RA treatment Xeljanz (tofacitinib); and Sanofi-Aventis' Cerezyme (imiglucerase-rch) for enzyme replacement therapy.
-
No more ‘wet ink’
Thursday | Jul 6 2017THE Therapeutic Goods Administration has advised that all licenses and certificates of Good Manufacturing Practice Compliance it issues will henceforth be signed "electronically" rather than requiring a wet ink signature, after a review of the relevant legislation identified that this was possible.
